Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study

Diabetes, Obesity and MetabolismEarly View RESEARCH LETTER Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study Chenyang Shi PharmD, Chenyang Shi PharmD orcid.org/0000-0002-0626-0781 Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorYijiong Tan MPharm, Yijiong Tan MPharm Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorShanshan Hu MPharm, Shanshan Hu MPharm Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorYingyi Qin PharmD, Yingyi Qin PharmD Department of Military Health Statistics, Naval Medical University, Shanghai, ChinaSearch for more papers by this authorYuanjun Tang MPharm, Yuanjun Tang MPharm Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorYufan Wang PharmD, Yufan Wang PharmD Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorGuorong Fan PharmD, Corresponding Author Guorong Fan PharmD guorfan@163.com Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China Correspondence Guorong Fan, Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, 210008, China. Email: guorfan@163.comSearch for more papers by this author Chenyang Shi PharmD, Chenyang Shi PharmD orcid.org/0000-0002-0626-0781 Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorYijiong Tan MPharm, Yijiong Tan MPharm Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorShanshan Hu MPharm, Shanshan Hu MPharm Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorYingyi Qin PharmD, Yingyi Qin PharmD Department of Military Health Statistics, Naval Medical University, Shanghai, ChinaSearch for more papers by this authorYuanjun Tang MPharm, Yuanjun Tang MPharm Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorYufan Wang PharmD, Yufan Wang PharmD Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorGuorong Fan PharmD, Corresponding Author Guorong Fan PharmD guorfan@163.com Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China Correspondence Guorong Fan, Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, 210008, China. Email: guorfan@163.comSearch for more papers by this author First published: 18 March 2024 https://doi.org/10.1111/dom.15552 Chenyang Shi, Yijiong Tan and Shanshan Hu contributed equally to this work. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat CONFLICT OF INTEREST STATEMENT The authors declare no potential conflicts of interest. Open Research PEER REVIEW The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15552. DATA AVAILABILITY STATEMENT The raw data supporting the conclusions of this article will be made available by the authors. Further inquiries can be directed to the corresponding author. Supporting Information Filename Description dom15552-sup-0001-supinfo.docxWord 2007 document , 39.6 KB Data S1. Supporting Information. dom15552-sup-0002-FigureS1.zipZip archive, 278.8 KB Figure S1. Changes in total cholesterol and uric acid when treatment with semaglutide compared to non-GLP-1RA from baseline to continuous clinical endpoints over time (T3 to T12). (A) Changes in total cholesterol. (B) Changes in uric acid. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Quan J, Zhao Z, Wang L, et al. Potential health and economic impact associated with achieving risk factor control in Chinese adults with diabetes: a microsimulation modelling study. Lancet Reg Health West Pac. 2023; 14(33):100690. doi:10.1016/j.lanwpc.2023.100690 10.1016/j.lanwpc.2023.100690 Google Scholar 2Pandey S, Mangmool S, Parichatikanond W. Multifaceted roles of GLP-1 and its analogs: a review on molecular mechanisms with a cardiotherapeutic perspective. Pharmaceuticals. 2023; 16(6): 836. doi:10.3390/ph16060836 10.3390/ph16060836 CASWeb of Science®Google Scholar 3Madsbad S, Holst JJ. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists. Cardiovasc Res. 2023; 119(4): 886-904. doi:10.1093/cvr/cvac112 10.1093/cvr/cvac112 CASPubMedWeb of Science®Google Scholar 4Ji L, Dong X, Li Y, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab. 2021; 23(2): 404-414. doi:10.1111/dom.14232 10.1111/dom.14232 CASPubMedWeb of Science®Google Scholar 5Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019; 45(5): 409-418. doi:10.1016/j.diabet 10.1016/j.diabet.2018.12.001 CASPubMedWeb of Science®Google Scholar 6Yale JF, Bodholdt U, Catarig AM, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. BMJ Open Diabetes Res Care. 2022; 10(2):e002619. doi:10.1136/bmjdrc-2021-002619 10.1136/bmjdrc-2021-002619 PubMedWeb of Science®Google Scholar 7Aroda VR, Faurby M, Lophaven S, Noone J, Wolden ML, Lingvay I. Insights into the early use of oral semaglutide in routine clinical practice: the IGNITE study. Diabetes Obes Metab. 2021; 23(9): 2177-2182. doi:10.1111/dom.14453 10.1111/dom.14453 CASPubMedWeb of Science®Google Scholar 8 World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310: 2191-2194. doi:10.1001/JAMA.2013.281053 10.1001/jama.2013.281053 CASPubMedWeb of Science®Google Scholar 9Rudofsky G, Catarig AM, Favre L, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Switzerland multicentre, prospective, observational study. Diabetes Res Clin Pract. 2021; 178:108931. doi:10.1016/j.diabres.2021.108931 10.1016/j.diabres.2021.108931 CASPubMedWeb of Science®Google Scholar 10Mohammedi K, Belhatem N, Berentzen TL, Catarig AM, Potier L. Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE France multicentre, prospective, observational study. Diabetes Obes Metab. 2023; 25(7): 1855-1864. doi:10.1111/dom.15045 10.1111/dom.15045 CASPubMedWeb of Science®Google Scholar 11Vilsbøll T, Lindahl CØ, Nielsen NF, Tikkanen CK. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: results from a nationwide observational study in people with type 2 diabetes. Diabetes Obes Metab. 2023; 25(6): 1740-1749. doi:10.1111/dom.15031 10.1111/dom.15031 PubMedWeb of Science®Google Scholar 12Garcia de Lucas MD, Miramontes-González JP, Avilés-Bueno B, Jiménez-Millán AI, Rivas-Ruiz F, Pérez-Belmonte LM. Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain. Front Endocrinol. 2022; 16(13):995646. doi:10.3389/fendo.2022.995646 10.3389/fendo.2022.995646 Google Scholar 13Simental-Mendía M, Linden-Torres E, Sánchez-García A, Sahebkar A, Simental-Mendía LE. Effect of glucagon-like peptide-1 receptor agonists on renal function: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2022; 88(8): 3566-3576. doi:10.1111/bcp.15304 10.1111/bcp.15304 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation